Why this evidence?
It is linked to a specific model version, scientific task, dataset, split, metric and source. That makes the claim inspectable rather than a detached marketing score.
Evo / Evo 2: Genomic sequence modelling
Peer-reviewed sequence-generation and prediction evaluations across biological scales.
Model versionEvo 2
TaskGenomic sequence modelling
DatasetGenomic sequence evaluations
SplitHeld-out genomic sequence evaluations
MetricDNA/RNA/protein generation
Replicationemerging
Reported byModel developers
Review statuscurated
Evidence confidence · limited
Confidence is multidimensional, not a universal model score.
Evidence completenessstrongModel version, task, dataset, split, metric, source and provenance fields.
Independent validationlimitedemerging
Source qualitystrongPeer-reviewed
Reproducibility evidencelimitedReflects documented replication status, not a universal reproducibility score.
Version specificitystrongEvo 2
Context applicabilitystrongDepends on task, split and explicit caveats; users must still validate their own context.
Contradiction reviewclearNo direct contradiction signal is currently queued.
BioAtlas reports evidence dimensions separately so a strong source cannot hide weak applicability, incomplete replication or unresolved contradiction.
Why?
Why should this evidence influence a decision?
Why not a universal score?
Performance can change with dataset, split, preprocessing, metric and context of use. BioAtlas therefore keeps confidence dimensions separate.
What could change the conclusion?
Independent replication, a better matched prospective dataset, a version change, a contradictory result or a more relevant validation protocol can reopen this evidence record.
Evidence boundary
What this claim does not prove.
- Generation quality does not establish biological function or safety.
- Evo and Evo 2 require version-specific evaluation.
BioAtlas groups benchmark claims only when task, dataset, split, metric and protocol context align. This record is not a universal model score.
Model context
Evo is a DNA foundation model that operates from nucleotides to whole genomes, predicting and designing across DNA, RNA and protein. Evo 2 (2025, with NVIDIA) scaled to 9.3 trillion base pairs across 128,000+ genomes spanning all domains of life — one of the largest biological models built. Evo designed a working CRISPR system (EvoCas9-1) that succeeded after just 11 tries.
Full evidence passport →Known model limitations
- Performance depends on the evaluation dataset and operating conditions.
- Task-specific benchmark results should not be compared across unlike domains.
- Outputs require task-specific scientific and experimental validation.